{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:40:03Z","timestamp":1770406803069,"version":"3.49.0"},"reference-count":427,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/13543776.2021.1970746","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:44:55Z","timestamp":1629719095000},"page":"89-114","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology\u2019s stages"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-8083","authenticated-orcid":false,"given":"Jabson Herber","family":"Profiro de Oliveira","sequence":"first","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-4748","authenticated-orcid":false,"given":"Igor Eduardo Silva","family":"Arruda","sequence":"additional","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0675-5485","authenticated-orcid":false,"given":"Jos\u00e9","family":"Izak Ribeiro de Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-7306","authenticated-orcid":false,"given":"Luise Lopes","family":"Chaves","sequence":"additional","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-915X","authenticated-orcid":false,"given":"M\u00f4nica Felts","family":"de La Rocca Soares","sequence":"additional","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-0294","authenticated-orcid":false,"given":"Jos\u00e9 Lamartine","family":"Soares-Sobrinho","sequence":"additional","affiliation":[{"name":"Federal University of Pernambuco","place":["Recife, Recife-Pernambuco"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldp046"},{"key":"e_1_3_6_4_1","unstructured":"World Health Organization (WHO). WHO Neglected tropical diseases: treating more than one billion people in 2017 [Internet]. Who. 2018 [cited 2001 Sep 20]. Available from: https:\/\/www.who.int\/neglected_diseases\/news\/treating-more-than-one-billion-people-2017\/en\/"},{"key":"e_1_3_6_5_1","unstructured":"WHO\/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases Third WHO report on neglected tropical diseases [Internet]. 2015. Available from:https:\/\/www.who.int\/neglected_diseases\/9789241564861\/en\/"},{"key":"e_1_3_6_6_1","unstructured":"World Health Organization (WHO). Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases [Internet]. Geneva (Switzerland); 2017. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/255011"},{"key":"e_1_3_6_7_1","unstructured":"WHO. Neglected tropical diseases [Internet]. 2019. [2019 Nov 13]. Available from: https:\/\/www.who.int\/neglected_diseases\/diseases\/en\/"},{"key":"e_1_3_6_8_1","unstructured":"END Fund. End fund Nigeria [Internet]. [cited 2021 Apr 06]. Available from: http:\/\/www.end.org\/ourimpact\/wherewework\/nigeria"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7357.176"},{"key":"e_1_3_6_10_1","first-page":"329","volume-title":"Advances in Parasitology","author":"Lee BY","year":"2015","unstructured":"Lee BY, Bartsch SM, Gorham KM. Economic and financial evaluation of neglected tropical diseases. In: Anderson RM, Bas\u00e1\u00f1ez MG, editors. Advances in Parasitology, Advances in Parasitology, Vol. 87. Cambridge, Massachusetts, EUA: Academic Press; 2015. 329\u2013417."},{"key":"e_1_3_6_11_1","unstructured":"The World Bank. Poverty [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/data.worldbank.org\/topic\/11"},{"key":"e_1_3_6_12_1","volume-title":"Resumo executivo (LC\/PUB.2020\/1-P)","author":"Comiss\u00e3o Econ\u00f4mica para a Am\u00e9rica Latina e o Caribe (CEPAL)","year":"2020","unstructured":"Comiss\u00e3o Econ\u00f4mica para a Am\u00e9rica Latina e o Caribe (CEPAL). Panorama Social da Am\u00e9rica Latina, 2019. In: Resumo executivo (LC\/PUB.2020\/1-P). Santiago: Publica\u00e7\u00e3o das Na\u00e7\u00f5es Unidas; 2020:\u00a01\u201316."},{"key":"e_1_3_6_13_1","unstructured":"General Assembly. Transforming our world: the 2030 agenda for sustainable development A\/RES\/70\/1 [Internet]. A New Era in Global Health. 2015. [cited 2021 Apr 06]. Available from: https:\/\/www.un.org\/ga\/search\/view_doc.asp?symbol=A\/RES\/70\/1&Lang=E"},{"key":"e_1_3_6_14_1","unstructured":"United Nations. Sustainable Development Goals [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/sdgs.un.org\/goals"},{"key":"e_1_3_6_15_1","unstructured":"WHO\/Department of control of neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases First WHO report on neglected tropical diseases [Internet]. 2010. [cited 2021 Apr 06]. Available from: https:\/\/www.who.int\/neglected_diseases\/resources\/9789241564090\/en\/"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002865"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000114"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61689-4"},{"key":"e_1_3_6_20_1","unstructured":"Institute for Health Metrics and Evaluation. Global Health Data Exchange [Internet]. [cited 2021 Jul 13]. Available from: http:\/\/ghdx.healthdata.org\/"},{"key":"e_1_3_6_21_1","unstructured":"Organizaci\u00f3n Panamericana de la Salud. M\u00e1s de 100 millones de personas padecen alguna enfermedad infecciosa desatendida en las Am\u00e9ricas [Internet]. 2015 [2001 Sep 20]. Available from: http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=10440%3A2015-100-millones-padecen-alguna-enfermedad-infecciosa-desatendida-en-las-americas&catid=740%3Anews-press-releases&Itemid=1926&lang=es"},{"key":"e_1_3_6_22_1","unstructured":"World Health Organization (WHO). Schistosomiasis [Internet]. 2020 [2021 Jan 27]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis"},{"key":"e_1_3_6_23_1","unstructured":"World Health Organization (WHO). Schistosomiasis (Bilharzia) [Internet]. [cited 2021 Jan 27]. Available from: https:\/\/www.who.int\/health-topics\/schistosomiasis#tab=tab_1"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1157\/13070382"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0186-2013"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70170-3"},{"key":"e_1_3_6_27_1","unstructured":"WHO. WHO Model List of Essential Medicines 20th List [Internet]. Geneva; 2019. [cited 2021 Apr 06]. Available from: https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists"},{"key":"e_1_3_6_28_1","unstructured":"History of Praziquantel [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/web.stanford.edu\/group\/parasites\/ParaSites2006\/Praziquantel\/history.html"},{"key":"e_1_3_6_29_1","doi-asserted-by":"crossref","unstructured":"Xu J Bergquist R Qian Y-J et al. China\u2013Africa and China\u2013Asia collaboration on schistosomiasis control. In 2016. p. 435\u2013466.","DOI":"10.1016\/bs.apar.2016.02.005"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-016-5253-5"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2005.07.011"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.6826.1"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-017-0256-8"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2014.04.002"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/20786190.2014.978121"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2016.01.006"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822008000300014"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2008.0185"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02761999000700077"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-1367-2013"},{"key":"e_1_3_6_41_1","unstructured":"World Health Organization (WHO). Chagas disease (American trypanosomiasis) [Internet]. [cited 2021 Jan 27]. Available from: https:\/\/www.who.int\/chagas\/epidemiology\/en\/"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00023-19"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2016.01.002"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005033"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003540"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2017.05.001"},{"key":"e_1_3_6_47_1","unstructured":"World Health Organization. WHO. Chagas disease (American trypanosomiasis) [Internet]. 2020 [2021 Jan 27]. Available from: https:\/\/www.who.int\/health-topics\/chagas-disease#tab=tab_1"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2018.11.008"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762007000900018"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02761909000200008"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-008-0992-6"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp357"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46652002000100006"},{"key":"e_1_3_6_54_1","first-page":"2","article-title":"Chagas Disease Cardiomyopathy","volume":"31","author":"Sim\u00f5es MV","year":"2018","unstructured":"Sim\u00f5es MV, Romano MMD, Schmidt A, et al. Chagas Disease Cardiomyopathy. Int J Cardiovasc Sci. 2018;31:2.","journal-title":"Int J Cardiovasc Sci"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960231205"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.03.004"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762011000600001"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00065-2"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-69912012000200011"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322009001200013"},{"issue":"1","key":"e_1_3_6_61_1","first-page":"53","article-title":"Complicacoes do megacolon e megaesofago chagasicos observadas em necropsia","volume":"27","author":"Rocha A","year":"1981","unstructured":"Rocha A, Henrique D, Borges E, et al. Complicacoes do megacolon e megaesofago chagasicos observadas em necropsia. Rev Goiana Med. 1981;27(1\/2):53\u201362.","journal-title":"Rev Goiana Med"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86821968000600005"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-39842002000500009"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.270_r.x"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.01.262"},{"key":"e_1_3_6_66_1","unstructured":"World Health Organization. WHO. Chagas disease (also known as American trypanosomiasis) [Internet]. 2020 [2021 Feb 1]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis)"},{"key":"e_1_3_6_67_1","unstructured":"LAFEPE. Guia de Compras do Benznidazol [Internet]. [cited 2021 Mar 17]. Available from: https:\/\/www.lafepe.pe.gov.br\/"},{"key":"e_1_3_6_68_1","unstructured":"DNDi. Paediatric Benznidazole [Internet]. [cited 2021 Mar 17]. Available from: https:\/\/dndi.org\/research-development\/portfolio\/paediatric-benznidazole\/"},{"key":"e_1_3_6_69_1","unstructured":"World Health Organization (WHO). Leishmaniasis [Internet]. [cited 2021 Jan 27]. Available from: https:\/\/www.who.int\/health-topics\/leishmaniasis#tab=tab_1"},{"key":"e_1_3_6_70_1","unstructured":"World Health Organization (WHO). Leishmaniasis [Internet]. [cited 2021 Jan 27]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006697"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2009.02306.x"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-7-3"},{"key":"e_1_3_6_74_1","unstructured":"World Health Organization (WHO). Leishmaniasis - Recommended treatment regimens for visceral leishmaniasis ranked by preference [Internet]. [cited 2021 Apr 06]. Available from: www.who.int%2Fleishmaniasis%2Fresearch%2F978924129496_pp67_71.pdf&usg=AOvVaw3DM0cdH6d2fDbRBVmpdbhs"},{"key":"e_1_3_6_75_1","unstructured":"World Health Organization. WHO. Schistosomiasis (Strategy) [Internet]. [cited 2021 Feb 1]. Available from: https:\/\/www.who.int\/schistosomiasis\/strategy\/en\/"},{"key":"e_1_3_6_76_1","unstructured":"World Health Organization (WHO). Leishmaniasis - Access to essential antileishmanial medicines and treatment [Internet]. [cited 2021 Feb 1]. Available from: https:\/\/www.who.int\/leishmaniasis\/research\/en\/"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-40422003000400018"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules14072317"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2004.03.001"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9290-9"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.01.033"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.3109\/10837459809028638"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-40422010000800018"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-013-0051-x"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9435-9"},{"issue":"5","key":"e_1_3_6_86_1","first-page":"1329","article-title":"Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma","volume":"38","author":"Koto KS","year":"2011","unstructured":"Koto KS, Lescault P, Brard L, et al. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol. 2011;38(5):1329\u20131341.","journal-title":"Int J Oncol"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762002000100001"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(01)00629-3"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks275"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2014.10.002"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0570-0"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328318978f"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00507974"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00031-7"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00389899"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(88)90192-5"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01941187"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0716-97602004000100007"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1086\/342415"},{"key":"e_1_3_6_100_1","volume-title":"Estudos estruturais da enzima nitrorredutase de Trypanosoma cruzi: caracteriza\u00e7\u00e3o do mecanismo de ativa\u00e7\u00e3o dos pr\u00f3-f\u00e1rmacos benznidazol e nifurtimox","author":"Cirqueira MDL","year":"2020","unstructured":"Cirqueira MDL. Estudos estruturais da enzima nitrorredutase de Trypanosoma cruzi: caracteriza\u00e7\u00e3o do mecanismo de ativa\u00e7\u00e3o dos pr\u00f3-f\u00e1rmacos benznidazol e nifurtimox. [Ribeir\u00e3o Preto]: Universidade de S\u00e3o Paulo; 2020."},{"issue":"1","key":"e_1_3_6_101_1","first-page":"10","article-title":"Mode of action of nifurtimox and other nitro-derivatives on Trypanosoma cruzi","volume":"40","author":"Stoppani AOM","year":"1980","unstructured":"Stoppani AOM, Docampo R. Mode of action of nifurtimox and other nitro-derivatives on Trypanosoma cruzi. Med Argentina. 1980;40(1):10\u201316.","journal-title":"Med Argentina"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05135-11"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1788-1797.2006"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066536"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.010"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00404-07"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.03.021"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(86)90001-0"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2018.04.001"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.8b01451"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104056"},{"issue":"6","key":"e_1_3_6_112_1","first-page":"91","article-title":"Study of the acute toxicity of the praziquantel using different routs of administration","author":"\u0406L K","year":"2018","unstructured":"\u0406L K, Romanina DM, Gladishev VV, et al. Study of the acute toxicity of the praziquantel using different routs of administration. Farm Zh. 2018;6:91\u201396.","journal-title":"Farm Zh"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ005"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003231"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx516"},{"issue":"1","key":"e_1_3_6_116_1","first-page":"19","article-title":"Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas\u2019 disease)","volume":"1","author":"Castro JA","year":"1988","unstructured":"Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas\u2019 disease). Biomed Environ Sci. 1988;1(1):19\u201333.","journal-title":"Biomed Environ Sci"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04660-14"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.06.006"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.10.030"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200707"},{"key":"e_1_3_6_121_1","first-page":"463575","article-title":"Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole","author":"Buschini A","year":"2009","unstructured":"Buschini A, Ferrarini L, Franzoni S, et al. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. J Parasitol Res. 2009;136:463575.","journal-title":"J Parasitol Res"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4800(89)90047-6"},{"issue":"3","key":"e_1_3_6_123_1","first-page":"249","article-title":"Rat liver nuclear nifurtimox nitroreductase activity","volume":"98","author":"De Toranzo EG","year":"1997","unstructured":"De Toranzo EG, Herrera DM, Castro JA. Rat liver nuclear nifurtimox nitroreductase activity. Res Commun Mol Pathol Pharmacol. 1997;98(3):249\u2013254.","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265935"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph7124267"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(97)00268-1"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2011.02.007"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw742"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.2.343"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000855"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066536"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndtplus\/sfr008"},{"key":"e_1_3_6_133_1","unstructured":"Diseases B (MD): NI of D and D and K. livertox: clinical and research information on drug-induced liver injury [internet]. 2012 [2021 Jan 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548946\/"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21476"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-2586-6_11"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90774-1"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.389"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(69)90067-9"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1086\/319211"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.riam.2009.06.003"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg472"},{"key":"e_1_3_6_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2016.10.001"},{"key":"e_1_3_6_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.04.031"},{"key":"e_1_3_6_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.176"},{"key":"e_1_3_6_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-002-0754-9"},{"key":"e_1_3_6_146_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02410-16"},{"key":"e_1_3_6_147_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-esdppp.76"},{"key":"e_1_3_6_148_1","unstructured":"FDA Approved Products: lampit (nifurtimox) oral tablets [Internet]. [cited 2021 Feb 20]. Available from: https:\/\/www.accessdata.fda.gov"},{"key":"e_1_3_6_149_1","first-page":"103","article-title":"Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: a candidate formulation for visceral leishmaniasis","volume":"2018","author":"Borborema SET","year":"1609","unstructured":"Borborema SET, Osso Junior JA, Tempone AG, et al. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: a candidate formulation for visceral leishmaniasis. Biomed Pharmacother. 1609\u201316;2018:103.","journal-title":"Biomed Pharmacother"},{"key":"e_1_3_6_150_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.982"},{"key":"e_1_3_6_151_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623309344088"},{"key":"e_1_3_6_152_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.1.169"},{"key":"e_1_3_6_153_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1970114505"},{"issue":"1","key":"e_1_3_6_154_1","first-page":"24","article-title":"[Determinants of serum pentamidine concentration in the human]","volume":"87","author":"V\u00f6hringer HF","year":"1992","unstructured":"V\u00f6hringer HF, Arasteh K, Link H, et al. [Determinants of serum pentamidine concentration in the human]. Med Klin. 1992;87(Suppl 1):24\u201329.","journal-title":"Med Klin"},{"key":"e_1_3_6_155_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp465"},{"key":"e_1_3_6_156_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02582-16"},{"key":"e_1_3_6_157_1","doi-asserted-by":"publisher","DOI":"10.1191\/0960327106het653oa"},{"issue":"3","key":"e_1_3_6_158_1","first-page":"51","article-title":"[Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author\u2019s transl)]","volume":"32","author":"Cerisola JA","year":"1977","unstructured":"Cerisola JA, Neves da Silva N, Prata A, et al. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author\u2019s transl)]. Bol Chil Parasitol. 1977;32(3\u20134):51\u201362.","journal-title":"Bol Chil Parasitol"},{"key":"e_1_3_6_159_1","doi-asserted-by":"publisher","DOI":"10.1086\/656917"},{"key":"e_1_3_6_160_1","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/1998052167"},{"key":"e_1_3_6_161_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201100422"},{"key":"e_1_3_6_162_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.10-0255"},{"key":"e_1_3_6_163_1","unstructured":"MSF. Milh\u00f5es aguardam inova\u00e7\u00f5es m\u00e9dicas para doen\u00e7as negligenciadas [Internet]. 2012 [2019 Oct 22]. Available from: https:\/\/www.msf.org.br\/noticias\/milhoes-aguardam-inovacoes-medicas-para-doencas-negligenciadas"},{"key":"e_1_3_6_164_1","unstructured":"DNDi. Desenvolvimento de novos medicamentos para doen\u00e7as negligenciadas ainda enfrenta falhas fatais [Internet]. 2013 [2019 Dec 10]. Available from: http:\/\/www.dndi.org\/2013\/media-centre\/langues-press-releases\/fatal-imbalance-2-po\/"},{"key":"e_1_3_6_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30005-2"},{"key":"e_1_3_6_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-210-6"},{"issue":"3","key":"e_1_3_6_167_1","first-page":"78","article-title":"Drug delivery systems: past, present and future","volume":"8","author":"Mehta VL","year":"1995","unstructured":"Mehta VL, Chatterjee N. Drug delivery systems: past, present and future. J Int Med Sci Acad. 1995;8(3):78\u201386.","journal-title":"J Int Med Sci Acad"},{"key":"e_1_3_6_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-101997-9.00001-1"},{"key":"e_1_3_6_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.03.054"},{"key":"e_1_3_6_170_1","volume-title":"Strategies to modify the drug release from pharmaceutical systems","author":"Bruschi M","year":"2015","unstructured":"Bruschi M. Strategies to modify the drug release from pharmaceutical systems. 1st Editio ed. Elsevier; 2015.","edition":"1"},{"key":"e_1_3_6_171_1","volume-title":"Pharmaceutical drug delivery market by route of administration and application: global opportunity analysis and industry forecast, 2019-2026","author":"Mukhekar S","year":"2020","unstructured":"Mukhekar S, Sumant O. Pharmaceutical drug delivery market by route of administration and application: global opportunity analysis and industry forecast, 2019-2026. Maharashtra (India): Allied Market Research; 2020."},{"key":"e_1_3_6_172_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5b09974"},{"key":"e_1_3_6_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.04.009"},{"key":"e_1_3_6_174_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-018-6122-9"},{"key":"e_1_3_6_175_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8BM00506K"},{"key":"e_1_3_6_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.03.020"},{"key":"e_1_3_6_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.08.009"},{"key":"e_1_3_6_178_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.5.1.45"},{"key":"e_1_3_6_179_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym11091380"},{"key":"e_1_3_6_180_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0136-y"},{"key":"e_1_3_6_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.09.003"},{"key":"e_1_3_6_182_1","volume-title":"The advantages of incremental pharmaceutical innovation","author":"Petkantchin V","year":"2012","unstructured":"Petkantchin V. The advantages of incremental pharmaceutical innovation. Bruxelles: Institut \u00c9conomique Molinari Economic Note; 2012."},{"key":"e_1_3_6_183_1","volume-title":"The Benefits of Incremental Innovation, focus on the pharmaceutical industry","author":"Globerman S","year":"2014","unstructured":"Globerman S, Kristina M. Lybecker. In: Globerman S, Kristina M. Lybecker, editors.The Benefits of Incremental Innovation, focus on the pharmaceutical industry. Montreal,\u00a0Toronto, Canada: Fraser institute.2014. 3\u201322."},{"key":"e_1_3_6_184_1","volume-title":"The value of incremental pharmaceutical innovation\u202f: innovation","author":"For B","year":"2009","unstructured":"For B, Patients I, Business I. The value of incremental pharmaceutical innovation\u202f: innovation. 2009."},{"key":"e_1_3_6_185_1","volume-title":"Incremental Innovation","author":"GSK - GlaxoSmithKline Communications and Government Affairs","year":"2014","unstructured":"GSK - GlaxoSmithKline Communications and Government Affairs. Incremental Innovation. GSK Public policy positions; 2014."},{"key":"e_1_3_6_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2017.02.019"},{"key":"e_1_3_6_187_1","unstructured":"Research GV. Controlled release drug delivery market size share & trends analysis report by technology (micro encapsulation targeted delivery) by release mechanism by application by region and segment forecasts 2020\u20132027 [Internet]. 2020. Available from: https:\/\/www.grandviewresearch.com\/press-release\/global-controlled-release-drug-delivery-market"},{"key":"e_1_3_6_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2017.01.003"},{"key":"e_1_3_6_189_1","doi-asserted-by":"publisher","DOI":"10.1257\/jep.27.1.23"},{"key":"e_1_3_6_190_1","unstructured":"How patents encourage innovation in technological development and deployment. [Internet]. [cited 2020 Jan 18]. Available from: https:\/\/www.irena.org\/inspire\/Intellectual-Property-Rights\/Innovation"},{"key":"e_1_3_6_191_1","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.82952"},{"key":"e_1_3_6_192_1","doi-asserted-by":"publisher","DOI":"10.1162\/003465398557221"},{"key":"e_1_3_6_193_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10961-010-9153-z"},{"key":"e_1_3_6_194_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2017.02.006"},{"key":"e_1_3_6_195_1","doi-asserted-by":"publisher","DOI":"10.3152\/147154403781776735"},{"key":"e_1_3_6_196_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016034516731"},{"key":"e_1_3_6_197_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.48.1.1.14273"},{"key":"e_1_3_6_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2010.06.019"},{"key":"e_1_3_6_199_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007921808138"},{"key":"e_1_3_6_200_1","unstructured":"Vrande VVD Jong JPJD Vanhaverbeke W. WIPO guide to using patent information [internet]. Vol. 29 Technovation. Geneva (Sswitzerland); 2009. \u00a0[cited 2021 Apr 06]. Available from: https:\/\/www.wipo.int\/edocs\/pubdocs\/en\/wipo_pub_l434_3.pdf"},{"issue":"1","key":"e_1_3_6_201_1","first-page":"42","article-title":"Patent database: their importance in prior art documentation and patent search","volume":"21","author":"Singh V","year":"2016","unstructured":"Singh V, Chakraborty K, Vincent L. Patent database: their importance in prior art documentation and patent search. J Intellect Prop Rights. 2016;21(1):42\u201356.","journal-title":"J Intellect Prop Rights"},{"key":"e_1_3_6_202_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4972(96)00031-4"},{"key":"e_1_3_6_203_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-012-0796-4"},{"key":"e_1_3_6_204_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-011-0457-z"},{"key":"e_1_3_6_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.technovation.2017.03.001"},{"key":"e_1_3_6_206_1","doi-asserted-by":"publisher","DOI":"10.1108\/02635571211232352"},{"key":"e_1_3_6_207_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0172-2190(03)00077-2"},{"key":"e_1_3_6_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cie.2016.04.009"},{"key":"e_1_3_6_209_1","doi-asserted-by":"publisher","DOI":"10.1016\/0048-7333(87)90027-8"},{"key":"e_1_3_6_210_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.052"},{"key":"e_1_3_6_211_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eswa.2007.01.033"},{"key":"e_1_3_6_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2008.10.007"},{"key":"e_1_3_6_213_1","doi-asserted-by":"publisher","DOI":"10.1080\/15583724.2015.1125918"},{"key":"e_1_3_6_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2016.08.020"},{"key":"e_1_3_6_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0172-2190(00)00040-5"},{"key":"e_1_3_6_216_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005667800235"},{"key":"e_1_3_6_217_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ipm.2006.11.011"},{"key":"e_1_3_6_218_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hitech.2003.09.003"},{"key":"e_1_3_6_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2012.10.014"},{"key":"e_1_3_6_220_1","doi-asserted-by":"publisher","DOI":"10.3390\/su8121252"},{"key":"e_1_3_6_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eswa.2019.112995"},{"key":"e_1_3_6_222_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.technovation.2008.10.006"},{"key":"e_1_3_6_223_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02016216"},{"key":"e_1_3_6_224_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2006.04.004"},{"issue":"5","key":"e_1_3_6_225_1","first-page":"28","article-title":"Using patent citation analysis to target\/value M&A candidates","volume":"45","author":"Breitzman A","year":"2002","unstructured":"Breitzman A, Thomas P. Using patent citation analysis to target\/value M&A candidates. Res Manag. 2002;45(5):28\u201336.","journal-title":"Res Manag"},{"key":"e_1_3_6_226_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.9.3.291"},{"key":"e_1_3_6_227_1","doi-asserted-by":"publisher","DOI":"10.1002\/cem.3041"},{"key":"e_1_3_6_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wpi.2018.05.005"},{"key":"e_1_3_6_229_1","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.41"},{"key":"e_1_3_6_230_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa.15.3"},{"key":"e_1_3_6_231_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa.12.29"},{"key":"e_1_3_6_232_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2016.1131267"},{"key":"e_1_3_6_233_1","doi-asserted-by":"publisher","DOI":"10.2174\/1877912304666140304000133"},{"key":"e_1_3_6_234_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221109788452294"},{"key":"e_1_3_6_235_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-017-0306-9"},{"key":"e_1_3_6_236_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.6.2.187"},{"key":"e_1_3_6_237_1","volume-title":"Technology Readiness Levels","author":"Mankins. JC","year":"1995","unstructured":"Mankins. JC. Technology Readiness Levels. 1995."},{"key":"e_1_3_6_238_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2334-5837.2016.00283.x"},{"key":"e_1_3_6_239_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2334-5837.2018.00502.x"},{"issue":"45","key":"e_1_3_6_240_1","first-page":"119","article-title":"N\u00edvel de Maturidade Tecnol\u00f3gica: uma sistem\u00e1tica para ordenar tecnologias","volume":"22","author":"Velho SRK","year":"2017","unstructured":"Velho SRK, Simonetti ML, Souza CRPD, et al. N\u00edvel de Maturidade Tecnol\u00f3gica: uma sistem\u00e1tica para ordenar tecnologias. Parc Estrat. 2017;22(n. 45):119\u2013140.","journal-title":"Parc Estrat"},{"key":"e_1_3_6_241_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actaastro.2009.03.058"},{"key":"e_1_3_6_242_1","doi-asserted-by":"publisher","DOI":"10.1109\/PICMET.2015.7273196"},{"key":"e_1_3_6_243_1","volume-title":"The TRL Scale as a Research & Innovation Policy Tool","author":"EARTO (European Association of Research and Technology Organizations)","year":"2014","unstructured":"EARTO (European Association of Research and Technology Organizations). The TRL Scale as a Research & Innovation Policy Tool. EARTO Recommendations, \u00a0Brussels (Belgium); 2014."},{"key":"e_1_3_6_244_1","unstructured":"European Commission. Drawing funding and financing scenarios for effective implementation of Smart Specialisation Strategies. JRC Technical reports. Seville (Spain); 2018."},{"key":"e_1_3_6_245_1","unstructured":"EMBRAPA. Sistema EMBRAPA de Gest\u00e3o Manual sobre o Uso da Escala TRL\/MRL. 2018."},{"key":"e_1_3_6_246_1","unstructured":"ISO. ISO 16290:2013 Space systems- Definition of the Technology Readiness Levels and their criteria of assessment. Iso 16290:2013. Geneva (Switzerland); 2013."},{"key":"e_1_3_6_247_1","unstructured":"European Union Horizons 2020 Framework Programme for Research and Innovation - European Commission Decision C (2014)4995 of 22 July 2014 \u201cHorizon 2020 work programme 2014\u20132015\u201d [Internet]. 2014. [cited 2021 Apr 06]. Available from: https:\/\/ec.europa.eu\/research\/participants\/data\/ref\/h2020\/wp\/2014_2015\/main\/h2020-wp1415-intro_en.pdf"},{"key":"e_1_3_6_248_1","doi-asserted-by":"publisher","DOI":"10.1002\/ente.201600805"},{"key":"e_1_3_6_249_1","unstructured":"Medical Countermeasure Products. DOD Medical TRLs and May 2008 HHS PHEMCE TRLs [Internet]. [cited 2019 Nov 5]. Available from: https:\/\/www.medicalcountermeasures.gov\/trl\/integrated-trls\/"},{"key":"e_1_3_6_250_1","volume-title":"Professor Iain Whitaker MA Cantab FRCS Plast DS. 3D bioprinting for surgical reconstruction & organ transplantation","author":"Jovic Cantab TM","year":"2018","unstructured":"Jovic Cantab TM MRCS, Jessop Cantab ZM MRCS, Firmin F, et al. Professor Iain Whitaker MA Cantab FRCS Plast DS. 3D bioprinting for surgical reconstruction & organ transplantation. London (UK): Future Medicine Ltd London; 2018."},{"key":"e_1_3_6_251_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2015.02.004"},{"key":"e_1_3_6_252_1","volume-title":"Development of an assessment methodology for demonstrating usability, technical maturity, and operational benefits of advanced medical technology","author":"NATO","year":"2010","unstructured":"NATO. Development of an assessment methodology for demonstrating usability, technical maturity, and operational benefits of advanced medical technology. Vol. TR-HFM-130. Brussels (Belgium): RTO\/NATO; 2010."},{"key":"e_1_3_6_253_1","doi-asserted-by":"publisher","DOI":"10.1002\/ghg.1422"},{"key":"e_1_3_6_254_1","volume-title":"From lab to large-scale development of clinically compliant nanopharmaceutics from lab to large-scale development of clinically compliant nanopharmaceutics","author":"Gabriela M","year":"2017","unstructured":"Gabriela M. From lab to large-scale development of clinically compliant nanopharmaceutics from lab to large-scale development of clinically compliant nanopharmaceutics. Coimbra (Portugal): Universidade de Coimbra; 2017."},{"key":"e_1_3_6_255_1","unstructured":"Of\u00edcio EMBRAPII n\u00b0098\/2019. Manual de orienta\u00e7\u00e3o operacional n\u00b0 02\/2019 [Internet]. [cited 2021 Apr 06]. Available from: https:\/\/embrapii.org.br\/wp-content\/images\/2019\/05\/0705_Orientacao_Operacional_02-19.pdf"},{"key":"e_1_3_6_256_1","doi-asserted-by":"publisher","DOI":"10.1109\/SERIP.2015.18"},{"key":"e_1_3_6_257_1","doi-asserted-by":"publisher","DOI":"10.1109\/AERO.2011.5747634"},{"key":"e_1_3_6_258_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2012.05.002"},{"key":"e_1_3_6_259_1","doi-asserted-by":"publisher","DOI":"10.1177\/0954405416668922"},{"key":"e_1_3_6_260_1","first-page":"82","volume-title":"Modelos para Analisar N\u00edveis de Prontid\u00e3o de Inova\u00e7\u00e3o [Internet]","author":"Contreras L","year":"2017","unstructured":"Contreras L, Lely A, \u00c1vila L, et al., (Colombia): \u201c\u2018An\u00e1lisis de Datos en Cuerpo Est\u00e1tico Basado en IMUS.\u2019\u201d Memorias de la S\u00e9ptima Conferencia Iberoamericana de Complejidad, Inform\u00e1tica y Cibern\u00e9tica: CICIC 2017. In: Modelos para Analisar N\u00edveis de Prontid\u00e3o de Inova\u00e7\u00e3o [Internet]. 2017. p. 82\u201386. Available from: http:\/\/www.iiis.org\/CDs2017\/CD2017Spring\/bookC1.htm"},{"issue":"1","key":"e_1_3_6_261_1","first-page":"17","article-title":"Integration maturity metrics: development of an integration readiness level","volume":"9","author":"Sauser B","year":"2010","unstructured":"Sauser B, Gove R, Forbes E, et al. Integration maturity metrics: development of an integration readiness level. Inf Knowl Syst Manag. 2010;9(1):17\u201346.","journal-title":"Inf Knowl Syst Manag"},{"key":"e_1_3_6_262_1","volume-title":"WEC technology performance levels (TPLs) - metric for successful development of economic WEC Technology","author":"Weber J","year":"2013","unstructured":"Weber J, Costello R, Ringwood J. WEC technology performance levels (TPLs) - metric for successful development of economic WEC Technology. Aalborg, Denmark: EWTEC2013; 2013."},{"key":"e_1_3_6_263_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rai.2015.08.001"},{"key":"e_1_3_6_264_1","doi-asserted-by":"publisher","DOI":"10.1109\/WSC.2018.8632541"},{"key":"e_1_3_6_265_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rser.2019.109258"},{"key":"e_1_3_6_266_1","doi-asserted-by":"publisher","DOI":"10.4043\/27527-MS"},{"key":"e_1_3_6_267_1","doi-asserted-by":"crossref","unstructured":"Engel DW Dalton AC Anderson KK et al. Development of Technology Readiness Level (TRL) Metrics and Risk Measures [Internet]. Richland WA (United States); 2012 Oct. [cited 2021 Apr 06]. Available from:http:\/\/www.osti.gov\/servlets\/purl\/1067968\/","DOI":"10.2172\/1067968"},{"key":"e_1_3_6_268_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4578"},{"key":"e_1_3_6_269_1","volume-title":"Pharmaceutical Development Manager","author":"DNDi","year":"2019","unstructured":"DNDi. Pharmaceutical Development Manager. Geneva, Switzerland: DNDi; 2019."},{"key":"e_1_3_6_270_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010006"},{"key":"e_1_3_6_271_1","volume-title":"Colloidal nanoscale carriers for active hydrophilic substances and method for producing same","author":"Cerize NNP","year":"2013","unstructured":"Cerize NNP, De Oliveira AM, R\u00e9 MI, et al. Colloidal nanoscale carriers for active hydrophilic substances and method for producing same. BR: WO2011156880A1; 2013."},{"key":"e_1_3_6_272_1","volume-title":"Processo para obten\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas utilizando alginato de s\u00f3dio como biopol\u00edmero e produto obtido","year":"2016","unstructured":"Processo para obten\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas utilizando alginato de s\u00f3dio como biopol\u00edmero e produto obtido. BR: BR102016030992; 2016."},{"key":"e_1_3_6_273_1","volume-title":"preferably schistosomiasis infection, contains poloxamer, soybean lecithin, sodium stearate, phosphatidyl ethanolamine, polyethylene glycol, praziquantel and glyceryl behenate","author":"Injection used for treating blood-sucking insect diseases","year":"2012","unstructured":"Injection used for treating blood-sucking insect diseases. preferably schistosomiasis infection, contains poloxamer, soybean lecithin, sodium stearate, phosphatidyl ethanolamine, polyethylene glycol, praziquantel and glyceryl behenate. CN: CN103381141-A; 2012."},{"key":"e_1_3_6_274_1","unstructured":"Leonardo Fernandes Fraceto Luciana de Matos Alves Pinto Eneida de Paula Antonio Carlos Senges Lino Marcelo Bispo de Jesus Yuji Takahata inventor. Composto de inclus\u00e3o entre b-ciclodextrina e praziquantel para tratamento de esquistossomose. BR: PI0401621\u20131; 2004."},{"key":"e_1_3_6_275_1","unstructured":"VANESSA CARLA FURTADO MOSQUEIRA LILIAN TEIXEIRA OLIVEIRA RAQUEL GOMES CASTANHEIRA inventor. Pharmaceutical composition used in human and veterinary medicine for treating Chagas disease. In: leishmaniasis African sleeping sickness and tumors comprises benznidazole drug associated with nanoestructures. BR: BR102013023902; 2013. 21."},{"key":"e_1_3_6_276_1","unstructured":"PEDRO JOS\u00c9 ROLIM NETO LESLIE RAPHAEL DE MOURA FERRAZ SALVANA PRISCYLLA MANSO COSTA LARISSA ARA\u00daJO ROLIM CYBELLY MARQUES DE MELO ROSALI MARIA FERREIRA DA SILVA SEVERINO ALVES J\u00daNIOR ALINNE \u00c9LIDA GON\u00c7ALVES ALVES D\u00c9BORA DOLORES SOUZA DA SILVA NASCINEMTO ISABELA ARA\u00daJO E AMARIZ inventor. Formula\u00e7\u00f5es farmac\u00eauticas contendo associa\u00e7\u00e3o de benznidazol e MOF\u2019s para obten\u00e7\u00e3o tecnol\u00f3gica de sistemas drug delivery. BR: BR1020160034086; 2016. 7."},{"key":"e_1_3_6_277_1","first-page":"9","volume-title":"do tipo emuls\u00e3o, microemuls\u00e3o e\/ou nanoemuls\u00e3o contendo benznidazol para o tratamento da doen\u00e7a de Chagas","year":"2012","unstructured":"Arn\u00f3bio Ant\u00f4nio da Silva Junior, Let\u00edcia Streck, Anselmo Gomes de Oliveira, inventor. Composi\u00e7\u00f5es e processo de produ\u00e7\u00e3o da forma l\u00edquida de administra\u00e7\u00e3o a base de sistemas lip\u00eddicos emulsionados. In: do tipo emuls\u00e3o, microemuls\u00e3o e\/ou nanoemuls\u00e3o contendo benznidazol para o tratamento da doen\u00e7a de Chagas. BR: BR1020120194287; 2012. 9."},{"key":"e_1_3_6_278_1","first-page":"16","volume-title":"Processo para obten\u00e7\u00e3o de complexos de inclus\u00e3o de benznidazol com derivados de ciclodextrinas","year":"2009","unstructured":"Processo para obten\u00e7\u00e3o de complexos de inclus\u00e3o de benznidazol com derivados de ciclodextrinas. BR: PI0903451\u20130; 2009. 16."},{"key":"e_1_3_6_279_1","volume-title":"Composi\u00e7\u00e3o e m\u00e9todo de produ\u00e7\u00e3o de sistemas nanoparticulados para libera\u00e7\u00e3o modificada de benznidazol","year":"2017","unstructured":"Jose Lamartine Soares Sobrinho, Pedro Jos\u00e9 Rolim Neto, Marc\u00edlio Sergio Soares da Cunha, Juan Torres Labandeira, inventor. Composi\u00e7\u00e3o e m\u00e9todo de produ\u00e7\u00e3o de sistemas nanoparticulados para libera\u00e7\u00e3o modificada de benznidazol. BR1020170244482; 2017."},{"key":"e_1_3_6_280_1","volume-title":"Composi\u00e7\u00f5es farmac\u00eauticas de posaconazol e benznidazol com incremento da dissolu\u00e7\u00e3o","year":"2016","unstructured":"Composi\u00e7\u00f5es farmac\u00eauticas de posaconazol e benznidazol com incremento da dissolu\u00e7\u00e3o. BR1020160238005; 2016."},{"key":"e_1_3_6_281_1","volume-title":"Formulation useful for controlled release of nifurtimox and treating chagas disease comprises nifurtimox, water-swellable hydrophilic polymer and binder e.g. microcrystalline cellulose","year":"2012","unstructured":"PEDRO JOS\u00c9 ROLIM NETO, CAMILA BEZERRA MELO FIGUEIR\u00caDO, PING I. LEE, ANA CARLA QUINTAS DE MEDEIROS VIEIRA, GIOVANNA CHRISTINNE ROCHA DE MEDEIROS SCHVER, JOS\u00c9 LAMARTINE SOARES SOBRINHO, Monica Felts de La Roca Soares, inventor. Formulation useful for controlled release of nifurtimox and treating chagas disease comprises nifurtimox, water-swellable hydrophilic polymer and binder e.g. microcrystalline cellulose. US: WO2013169925-A1; 2012."},{"key":"e_1_3_6_282_1","volume-title":"Preparation of compounds used for preparing composition for treating e.g. leishmaniasis, comprises mixing antimony derivatives with cyclodextrins in aqueous solution or in solid state","year":"2006","unstructured":"BEJARANO ROSEMARY OCHOA, DEMELO ALAN LANE, DEMICHELE CYNTHIA PERES, FERREIRA LUCAS ANTONIO MIRANDA, FREZARD FREDERIC JEAN GEORGES, MILLAN RUBEN DARIO SINISTERRA, inventor. Preparation of compounds used for preparing composition for treating e.g. leishmaniasis, comprises mixing antimony derivatives with cyclodextrins in aqueous solution or in solid state. BR: WO2006000069; 2006."},{"key":"e_1_3_6_283_1","first-page":"29","volume-title":"Processo de prepara\u00e7\u00e3o de compostos entre as ciclodextrinas ou seus derivados e o antim\u00c8nio ou seus derivados, de formula\u00e7\u00f5es farmaceuticas contendo esses compostos e produtos associados, para o tratamento das leishmanioses e da esquistossomose","year":"2004","unstructured":"Cynthia Peres Demichele, Frederic Jean Georges Frezard, Alan Lane de Melo, Lucas Antonio Miranda Ferreira, Ruben Dario Sinisterra Millan; Rosemary Ochoa Bejarano, inventors. Processo de prepara\u00e7\u00e3o de compostos entre as ciclodextrinas ou seus derivados e o antim\u00c8nio ou seus derivados, de formula\u00e7\u00f5es farmaceuticas contendo esses compostos e produtos associados, para o tratamento das leishmanioses e da esquistossomose. BR: C10304952\u20133 (PI0304952-3); 2004. 29."},{"key":"e_1_3_6_284_1","volume-title":"Nanoparticles used for preventing and treating pathologies due to infection with Leishmania in animal and humans comprise polylactic acid shell and aqueous core including antimonial compound","year":"2014","unstructured":"Domenico BRITTI, Donato Cosco, Massimo Fresta, Donatella Paolino, Elena TRAPASSO, inventors. Nanoparticles used for preventing and treating pathologies due to infection with Leishmania in animal and humans comprise polylactic acid shell and aqueous core including antimonial compound. WO2015177820; 2014."},{"key":"e_1_3_6_285_1","volume-title":"Liposome encapsulated anti-leishmaniasis antimonial drug|formed by wetting lipid film with drug soln., mixing and removing excess drug soln","year":"1980","unstructured":"ALVING CARL R, STECK EDGAR A, inventors. Liposome encapsulated anti-leishmaniasis antimonial drug|formed by wetting lipid film with drug soln., mixing and removing excess drug soln. US: US4186183; 1980."},{"key":"e_1_3_6_286_1","volume-title":"Pharmaceutical composition used for producing medicament for treatment of visceral leishmaniasis in mammals, comprises combination of conventional liposomes and prolonged circulating liposomes incorporating antileishmanial drugs","year":"2012","unstructured":"APARECIDA REZENDE SIMONE, GUILHERME AZEVEDO ERLY, JEAN GEORGES FREZARD FREDERIC, MAGNO DA SILVA SYDNEI, PERES DEMICHELI CYNTHIA, RIO RIBEIRO RAUL, inventors. Pharmaceutical composition used for producing medicament for treatment of visceral leishmaniasis in mammals, comprises combination of conventional liposomes and prolonged circulating liposomes incorporating antileishmanial drugs. BR: WO2013131164; 2012."},{"key":"e_1_3_6_287_1","volume-title":"Nanocarreadores coloidais para veicula\u00e7\u00e3o t\u00f3pica do antimoniato de meglumina","year":"2016","unstructured":"NAT\u00c1LIA NETO PEREIRA CERIZE; THAIS ARAG\u00c3O HOROIWA, Adriano Marim de Oliveira, inventors. Nanocarreadores coloidais para veicula\u00e7\u00e3o t\u00f3pica do antimoniato de meglumina. BR: BR1020160034434; 2016."},{"key":"e_1_3_6_288_1","volume-title":"Stable liposome(s) of antimony contg. drug|for treatment of Leishmania infection","year":"1983","unstructured":"RAO LEBURU S, inventor. Stable liposome(s) of antimony contg. drug|for treatment of Leishmania infection. GB: US4594241-A; 1983."},{"key":"e_1_3_6_289_1","volume-title":"Liposomal formulation useful as leishmanicidal agent, comprises single dose of antileishmanial antimonial drug encapsulated in cationic liposome consisting of neutral lipid and cationic lipid in specific molar ratio","year":"2005","unstructured":"ALI NAHID, BHOWMICK SWATI P, GHOSE JAYEETA, inventor. Liposomal formulation useful as leishmanicidal agent, comprises single dose of antileishmanial antimonial drug encapsulated in cationic liposome consisting of neutral lipid and cationic lipid in specific molar ratio. IN: US2012207821; 2005."},{"key":"e_1_3_6_290_1","volume-title":"Liposomal formulation useful as leishmanicidal agent for treatment of kala azar, comprises amount of antileishmanial antimonial drugs encapsulated in sub optimal dose of cationic liposome, where ratio of lipid to drug is specified","author":"Reports JC","year":"2005","unstructured":"MARIA NORMA MELO; JOS\u00c9 DIAS CORREA J\u00daNIOR; FR\u00c9D\u00c9RIC JEAN GEORGES FR\u00c9ZARD; BET\u00c2NIA MARA ALVARENGA; KELLY CRISTINA KATO, inventors. Reports JC, Indicators ES. Liposomal formulation useful as leishmanicidal agent for treatment of kala azar, comprises amount of antileishmanial antimonial drugs encapsulated in sub optimal dose of cationic liposome, where ratio of lipid to drug is specified. IN: US2007026061; 2005."},{"key":"e_1_3_6_291_1","volume-title":"Processo de prepara\u00e7\u00e3o de nanocomp\u00f3sitos fosfatados biocompat\u00edveis, produtos e usos","year":"2013","unstructured":"Processo de prepara\u00e7\u00e3o de nanocomp\u00f3sitos fosfatados biocompat\u00edveis, produtos e usos. BR: BR102013032731; 2013."},{"key":"e_1_3_6_292_1","volume-title":"Pharmaceutical composition for preparing medicine for treating parasitosis and infectious skin diseases in dermis regions e.g. leishmaniasis, comprises antiparasitic medicine that is encapsulated in poly(lactic-co-glycolic acid) particles","year":"2011","unstructured":"ALVES BANDEIRA FALCAO CAMILA, PACIENZA LIMA WALLACE, ROSSI BERGMANN BARTIRA, inventors. Pharmaceutical composition for preparing medicine for treating parasitosis and infectious skin diseases in dermis regions e.g. leishmaniasis, comprises antiparasitic medicine that is encapsulated in poly(lactic-co-glycolic acid) particles. BR: WO<\/Collab>2013010238; 2011."},{"key":"e_1_3_6_293_1","volume-title":"Topical pharmaceutical formulation used for treating fungal infection (cutaneous and mucocutaneous mycoses) and parasitic infections (cutaneous leishmaniasis) in humans, comprises complex of monomeric amphotericin B and gamma-cyclodextrin","year":"2010","unstructured":"BILBAO RAMOS PABLO ESTANISLAO; BOLAS FERNANDEZ FRANCISCO, DEA AYUELA MARIA AUXILIADORA, MOLERO MARTIN-PORTUGUES GLORIA, NOMBELA CANO CESAR; RUIZ SALDANA HELGA KARINA, SERRANO LOPEZ REMEDIOS, TORRADO DURAN JUAN JOSE, VEGAS SANCHEZ MARIA DEL CARMEN, inventors.Topical pharmaceutical formulation used for treating fungal infection (cutaneous and mucocutaneous mycoses) and parasitic infections (cutaneous leishmaniasis) in humans, comprises complex of monomeric amphotericin B and gamma-cyclodextrin. ES: WO2012042072; 2010."},{"key":"e_1_3_6_294_1","volume-title":"Processo de obten\u00e7\u00e3o de nanopart\u00edculas polim\u00e9ricas contendo o f\u00e1rmaco anfotericina B","year":"2011","unstructured":"Maria Mainardes, Najeh Maissar Kahalil, Diani Mesa Casa, Luciana Facco Dalmolin, Talita Cristina Moreira Moraes Carraro, Calorine Antunes Danziato, inventors.Processo de obten\u00e7\u00e3o de nanopart\u00edculas polim\u00e9ricas contendo o f\u00e1rmaco anfotericina B. BR: PI1107205\u20139; 2011."},{"key":"e_1_3_6_295_1","volume-title":"Sistema micelar termo revers\u00edvel contendo anfotericina b para administra\u00e7\u00e3o subcut\u00e2nea e t\u00f3pica no tratamento da leishmaniose visceral e tegumentar","year":"2014","unstructured":"OS\u00c9 MARIO BARICHELLO, RENATA ALVES DE OLIVEIRA E CASTRO, LUCAS ANDRADE FERREIRA, ELIETE MARIA COSTA, ANA PAULA DE BATTISTI RIBEIRO, SIMONE APARECIDA REZENDE, inventors. Sistema micelar termo revers\u00edvel contendo anfotericina b para administra\u00e7\u00e3o subcut\u00e2nea e t\u00f3pica no tratamento da leishmaniose visceral e tegumentar. BR1020140307729; 2014."},{"key":"e_1_3_6_296_1","volume-title":"Uso de nanopart\u00edculas de quitosana e condroitina para o tratamento de leishmaniose","year":"2013","unstructured":"ANDR\u00c9 AUGUSTO GOMES FARACO, JU\u00c7ARA RIBEIRO FRANCA, TATIANA GOMES RIBEIRO, RACHEL OLIVEIRA CASTILHO, EDUARDO ANTONIO FERRAZ COELHO, MIGUEL ANGEL CH\u00c1VEZ FUMAGALLI , inventors. Uso de nanopart\u00edculas de quitosana e condroitina para o tratamento de leishmaniose. BR1020130178810; 2013."},{"key":"e_1_3_6_297_1","volume-title":"Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof","year":"2006","unstructured":"Shoukath M Ali, Moghis U Ahmad, Ateeq Ahmad; Saifuddin Sheikh, Imran Ahmad, inventors. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof. WO2008127358; 2006."},{"key":"e_1_3_6_298_1","volume-title":"Composition, useful for the treatment of infections, comprises sterol enriched mixed lamellarity amphotericin intercalating liposomes in aqueous suspension","year":"2004","unstructured":"Jitendra Nath Verma, Lily Verma, Krishan Kumar Tripathi, inventors. Composition, useful for the treatment of infections, comprises sterol enriched mixed lamellarity amphotericin intercalating liposomes in aqueous suspension. WO2005120460; 2004."},{"key":"e_1_3_6_299_1","volume-title":"Targeted pharmaceutical composition loaded with amphotericin B and adriamycin together and application thereof","year":"2019","unstructured":"HU JING, WEI PENG, YIN JIAN, inventors. Targeted pharmaceutical composition loaded with amphotericin B and adriamycin together and application thereof. CN: CN110801433; 2019."},{"key":"e_1_3_6_300_1","volume-title":"Formula\u00e7\u00e3o de nanoemuls\u00f5es contendo miltefosina em associa\u00e7\u00e3o com betaglucana extra\u00edda de saccharomyces cerevisiae por micro-ondas e seu uso","year":"2019","unstructured":"VANESSA CRISTINA RESCIA, CLAUDETE JUSTINA VALDUGA, SUSANA NOGUEIRA DINIZ, inventors. Formula\u00e7\u00e3o de nanoemuls\u00f5es contendo miltefosina em associa\u00e7\u00e3o com betaglucana extra\u00edda de saccharomyces cerevisiae por micro-ondas e seu uso. BR: BR102019007133; 2019."},{"key":"e_1_3_6_301_1","first-page":"5","volume-title":"Formula\u00e7\u00e3o lipossomal para o tratamento das leishmanioses","year":"2017","unstructured":"SYDNEI MAGNO DA SILVA, KAREN FERRAZ FARIA, FREDERIC JEAN GEORGES FREZARD, JULIANE SOUSA LANZA, RENATA CRISTINA DE PAULA, inventors. Formula\u00e7\u00e3o lipossomal para o tratamento das leishmanioses. BR: BR1020170025829; 2017. 5."},{"key":"e_1_3_6_302_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1166"},{"key":"e_1_3_6_303_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2007.05.110"},{"key":"e_1_3_6_304_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2013.10.007"},{"key":"e_1_3_6_305_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73848-w"},{"key":"e_1_3_6_306_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105234"},{"key":"e_1_3_6_307_1","unstructured":"Molina I. Final report summary - BERENICE (benznidazol and triazol research group for nanomedicine and innovation on chagas disease) [Internet]. EUROPEAN COMMISSION. [cited 2021 Mar 4]. Available from: https:\/\/cordis.europa.eu\/project\/id\/305937\/reporting"},{"key":"e_1_3_6_308_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.11.027"},{"key":"e_1_3_6_309_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9346-7"},{"key":"e_1_3_6_310_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10973-016-5759-1"},{"key":"e_1_3_6_311_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S167285"},{"key":"e_1_3_6_312_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100914"},{"key":"e_1_3_6_313_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101784"},{"key":"e_1_3_6_314_1","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2013.851302"},{"key":"e_1_3_6_315_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.1045"},{"key":"e_1_3_6_316_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22508"},{"key":"e_1_3_6_317_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200504-613PP"},{"key":"e_1_3_6_318_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S596"},{"key":"e_1_3_6_319_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjps.2018.04.001"},{"key":"e_1_3_6_320_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S52634"},{"key":"e_1_3_6_321_1","doi-asserted-by":"crossref","unstructured":"A. A A. M F. P. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. In: Recent Advances in Novel Drug Carrier Systems [Internet]. InTech; 2012. [cited 2021\u00a0Apr 6].\u00a0Available from: http:\/\/www.intechopen.com\/books\/recent-advances-in-novel-drug-carrier-systems\/lipid-nanoparticulate-drug-delivery-systems-a-revolution-in-dosage-form-design-and-development","DOI":"10.5772\/50486"},{"key":"e_1_3_6_322_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/750891"},{"key":"e_1_3_6_323_1","first-page":"197","article-title":"Paromomycin-loaded mannosylated chitosan nanoparticles: synthesis, characterization and targeted drug delivery against leishmaniasis","author":"Esfandiari F","year":"2019","unstructured":"Esfandiari F, Motazedian MH, Asgari G, et al. Paromomycin-loaded mannosylated chitosan nanoparticles: synthesis, characterization and targeted drug delivery against leishmaniasis. Acta Trop. 2019;197.","journal-title":"Acta Trop"},{"key":"e_1_3_6_324_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.02.145"},{"key":"e_1_3_6_325_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0716-97602002000100007"},{"key":"e_1_3_6_326_1","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/1997044331"},{"key":"e_1_3_6_327_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00790"},{"key":"e_1_3_6_328_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.12.030"},{"key":"e_1_3_6_329_1","unstructured":"JOS\u00c9 DIAS CORREA J\u00daNIOR FR\u00c9D\u00c9RIC JEAN GEORGES FR\u00c9ZARD BET\u00c2NIA MARA ALVARENGA MARIA NORMA MELO KELLY CRISTINA KATO inventors. Nanocomp\u00f3sitos fosfatados biocompat\u00edveis contendo antim\u00f4nio processo de prepara\u00e7\u00e3o e usos. BR: BR132015031111; 2015."},{"key":"e_1_3_6_330_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200007000-00056"},{"key":"e_1_3_6_331_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl141"},{"key":"e_1_3_6_332_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12996"},{"key":"e_1_3_6_333_1","doi-asserted-by":"publisher","DOI":"10.1086\/515085"},{"key":"e_1_3_6_334_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2017.07.001"},{"key":"e_1_3_6_335_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.03.053"},{"key":"e_1_3_6_336_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr432"},{"key":"e_1_3_6_337_1","doi-asserted-by":"publisher","DOI":"10.4103\/0110-5558.76435"},{"key":"e_1_3_6_338_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020055"},{"key":"e_1_3_6_339_1","doi-asserted-by":"publisher","DOI":"10.1515\/abm-2018-0002"},{"key":"e_1_3_6_340_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2019.08.015"},{"key":"e_1_3_6_341_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.752"},{"key":"e_1_3_6_342_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108942"},{"key":"e_1_3_6_343_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2.1.335"},{"key":"e_1_3_6_344_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.05.042"},{"key":"e_1_3_6_345_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tca.2010.07.011"},{"key":"e_1_3_6_346_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.11.018"},{"key":"e_1_3_6_347_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.07.030"},{"key":"e_1_3_6_348_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051161"},{"key":"e_1_3_6_349_1","doi-asserted-by":"publisher","DOI":"10.1021\/js950534b"},{"key":"e_1_3_6_350_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.10.044"},{"key":"e_1_3_6_351_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9690-2"},{"key":"e_1_3_6_352_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9274-6"},{"key":"e_1_3_6_353_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.03.026"},{"key":"e_1_3_6_354_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1773-2247(04)50003-5"},{"key":"e_1_3_6_355_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10847-011-0077-5"},{"key":"e_1_3_6_356_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2005.73.901"},{"key":"e_1_3_6_357_1","volume-title":"Edital MCT\/CNPq\/CTSa\u00fade n\u00b0 11\/2006 Estudo da Dengue","author":"CNPq","year":"2006","unstructured":"CNPq. Edital MCT\/CNPq\/CTSa\u00fade n\u00b0 11\/2006 Estudo da Dengue. Brasilia(Brasil); 2006."},{"key":"e_1_3_6_358_1","volume-title":"Edital MCT\/CNPq\/MS-SCTIE-DECIT n\u00b0 25\/2006 Estudo de Doen\u00e7as Negligenciadas","author":"CNPq","year":"2006","unstructured":"CNPq. Edital MCT\/CNPq\/MS-SCTIE-DECIT n\u00b0 25\/2006 Estudo de Doen\u00e7as Negligenciadas. Brasilia(Brasil); 2006."},{"key":"e_1_3_6_359_1","volume-title":"Edital MCT\/CNPq\/CT-Sa\u00fade\/MS\/SCTIE\/DECIT n\u00b0 34\/2008 Doen\u00e7as Negligenciadas","author":"CNPq","year":"2008","unstructured":"CNPq. Edital MCT\/CNPq\/CT-Sa\u00fade\/MS\/SCTIE\/DECIT n\u00b0 34\/2008 Doen\u00e7as Negligenciadas. Brasilia(Brasil); 2008."},{"key":"e_1_3_6_360_1","volume-title":"Edital MCT\/CNPq N\u00b0 073 2009 PRONEX Rede Dengue","author":"CNPq","year":"2009","unstructured":"CNPq. Edital MCT\/CNPq N\u00b0 073 2009 PRONEX Rede Dengue. Brasilia(Brasil); 2009."},{"key":"e_1_3_6_361_1","volume-title":"Edital n\u00b0 41\/2012 Conv\u00eanio CNPq\/GSK (GlaxoSmithKline)","author":"CNPq","year":"2012","unstructured":"CNPq. Edital n\u00b0 41\/2012 Conv\u00eanio CNPq\/GSK (GlaxoSmithKline). Brasilia(Brasil); 2012."},{"key":"e_1_3_6_362_1","volume-title":"Edital MCTI-CNPq-MS-SCTIE-Decit n\u00b0 40\u20132012 Pesquisa em Doen\u00e7as Negligenciadas","author":"CNPq","year":"2012","unstructured":"CNPq. Edital MCTI-CNPq-MS-SCTIE-Decit n\u00b0 40\u20132012 Pesquisa em Doen\u00e7as Negligenciadas. Brasilia(Brasil); 2012."},{"key":"e_1_3_6_363_1","volume-title":"Edital CNPq\/MS\/SCTIE\/DECIT n\u00b0 37\/2014 Pesquisas sobre Helmint\u00edases","author":"CNPq","year":"2014","unstructured":"CNPq. Edital CNPq\/MS\/SCTIE\/DECIT n\u00b0 37\/2014 Pesquisas sobre Helmint\u00edases. Brasilia(Brasil); 2014."},{"key":"e_1_3_6_364_1","volume-title":"Edital CNPq-MS-SCTIE-DECIT n\u00b0 31\/2014 Pesquisas sobre Doen\u00e7a de Chagas","author":"CNPq","year":"2014","unstructured":"CNPq. Edital CNPq-MS-SCTIE-DECIT n\u00b0 31\/2014 Pesquisas sobre Doen\u00e7a de Chagas. Brasilia(Brasil); 2014."},{"key":"e_1_3_6_365_1","volume-title":"Edital CNPq\/MS\/SCTIE\/DECIT\/SVS\/DST n\u00b0 30\/2014","author":"CNP","year":"2014","unstructured":"CNP. Edital CNPq\/MS\/SCTIE\/DECIT\/SVS\/DST n\u00b0 30\/2014. Brasilia(Brasil); 2014."},{"key":"e_1_3_6_366_1","volume-title":"Edital CNPq\/MS\/SCTIE\/DECIT n\u00b0 32\/2014 Pesquisas sobre Leishmanioses","author":"CNPq","year":"2014","unstructured":"CNPq. Edital CNPq\/MS\/SCTIE\/DECIT n\u00b0 32\/2014 Pesquisas sobre Leishmanioses. Brasilia(Brasil); 2014."},{"key":"e_1_3_6_367_1","unstructured":"BRASIL. Lei [Internet]. BRASIL; 2004. Available from: http:\/\/www.planalto.gov.br\/ccivil_03\/_ato2004-2006\/2004\/lei\/l10.973.htm"},{"key":"e_1_3_6_368_1","unstructured":"BRASIL - MINIST\u00c9RIO DA CI\u00caNCIA TECNOLOGIA IEC. Pol\u00edtica de propriedade intelectual das institui\u00e7\u00f5es cient\u00edficas tecnol\u00f3gicas e de inova\u00e7\u00e3o do brasil relat\u00f3rio formict 2016 pol\u00edtica de propriedade intelectual das institui\u00e7\u00f5es cient\u00edficas e tecnol\u00f3gicas e de inova\u00e7\u00e3o do brasil [internet]. 2017. [cited 2021 Apr 6]. Available from: https:\/\/www.mctic.gov.br\/mctic\/export\/sites\/institucional\/tecnologia\/propriedade_intelectual\/arquivos\/Relatorio-Formict-Ano-Base-2016.pdf"},{"key":"e_1_3_6_369_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2010.02.002"},{"key":"e_1_3_6_370_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0048-7333(99)00100-6"},{"key":"e_1_3_6_371_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2010.04.002"},{"key":"e_1_3_6_372_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2006.04.009"},{"key":"e_1_3_6_373_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2006.04.005"},{"key":"e_1_3_6_374_1","volume-title":"Patentes de universidades e institutos p\u00fablicos de pesquisa e a transfer\u00eancia de tecnologia para empresas no Brasil","author":"P\u00f3voa LMC","year":"2008","unstructured":"P\u00f3voa LMC. Patentes de universidades e institutos p\u00fablicos de pesquisa e a transfer\u00eancia de tecnologia para empresas no Brasil. Universidade Federal de Minas Gerais; 2008."},{"key":"e_1_3_6_375_1","volume-title":"Patentes acad\u00eamicas no Brasil: um novo panorama de contribui\u00e7\u00e3o das universidades na via PCT","author":"Silva K","year":"2014","unstructured":"Silva K. Patentes acad\u00eamicas no Brasil: um novo panorama de contribui\u00e7\u00e3o das universidades na via PCT. Lisboa, Portugal: Lisboa School of Economics & Management; 2014."},{"key":"e_1_3_6_376_1","unstructured":"World Health Organization (WHO). WHO Lymphatic filariasis Partnership [Internet]. [cited 2020 Sep 2]. Available from: https:\/\/www.who.int\/lymphatic_filariasis\/partnership\/en\/"},{"key":"e_1_3_6_377_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.embor858"},{"key":"e_1_3_6_378_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2011.01.011"},{"issue":"10","key":"e_1_3_6_379_1","first-page":"1047","article-title":"A breakthrough in R&D for neglected diseases: new ways to get the drugs we need (PLoS Medicine (2005) 2:9","volume":"2","author":"Erratum MM","year":"2005","unstructured":"Erratum MM. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need (PLoS Medicine (2005) 2:9. PLoS Med. 2005;2(10):1047.","journal-title":"PLoS Med"},{"key":"e_1_3_6_380_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.inhe.2010.04.002"},{"key":"e_1_3_6_381_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1008268"},{"issue":"1","key":"e_1_3_6_382_1","first-page":"9","article-title":"Driving innovations across the valley of death","volume":"48","author":"Wessner CW","year":"2005","unstructured":"Wessner CW. Driving innovations across the valley of death. Res Manag. 2005 Jan 22;48(1):9\u201312.","journal-title":"Res Manag"},{"key":"e_1_3_6_383_1","volume-title":"The advanced technology program: reform with a purpose","author":"Evans DL","year":"2002","unstructured":"Evans DL. The advanced technology program: reform with a purpose. 2002."},{"key":"e_1_3_6_384_1","doi-asserted-by":"publisher","DOI":"10.1038\/453840a"},{"key":"e_1_3_6_385_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-5885.2010.00724.x"},{"key":"e_1_3_6_386_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-7364-7-5"},{"key":"e_1_3_6_387_1","volume-title":"Transitioning to Private-Sector Financing: characteristics of Success, \u00a0Colorado USA: NREL\/MP-720-31192","author":"Boyle LMMJBC","year":"2002","unstructured":"Boyle LMMJBC. Transitioning to Private-Sector Financing: characteristics of Success, \u00a0Colorado USA: NREL\/MP-720-31192. 2002."},{"key":"e_1_3_6_388_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.01.012"},{"key":"e_1_3_6_389_1","unstructured":"Murphy LM Edwards PL. Bridging the valley of death: transitioning from public to private sector financing. NREL\/MP-720-34036 [Internet]. Colorado (USA); 2003. [cited 2021 Apr 06]. Available from: https:\/\/www.nrel.gov\/docs\/gen\/fy03\/34036.pdf"},{"key":"e_1_3_6_390_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000265"},{"key":"e_1_3_6_391_1","unstructured":"Translational science and the \u201cvalley of death\u201d [internet]. 2015 [2019 Dec 10]. Available from: https:\/\/www.openphilanthropy.org\/blog\/translational-science-and-valley-death"},{"key":"e_1_3_6_392_1","unstructured":"Daniels N. How can the uk close the valley of death gap? [internet]. The Institute of Materials Minerals and Mining. 2016 [2019 Dec 10]. Available from: https:\/\/www.iom3.org\/materials-world-magazine\/feature\/2016\/jan\/05\/how-can-uk-close-valley-death-gap"},{"key":"e_1_3_6_393_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006653"},{"key":"e_1_3_6_394_1","first-page":"12(66):1\u201310","article-title":"Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial","author":"Omollo R","year":"2011","unstructured":"Omollo R, Alexander N, Edwards T, et al. Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011 Jun;12(66):1\u201310.","journal-title":"Trials"},{"issue":"2","key":"e_1_3_6_395_1","first-page":"197","article-title":"Safety evaluation of topical application of nano-liposomal form of amphotericin B (Sinaampholeish) on healthy volunteers: phase I clinical trial","volume":"14","author":"Eskandari SE","year":"2019","unstructured":"Eskandari SE, Firooz A, Nassiri-Kashani M, et al. Safety evaluation of topical application of nano-liposomal form of amphotericin B (Sinaampholeish) on healthy volunteers: phase I clinical trial. Iran J Parasitol. 2019;14(2):197\u2013203.","journal-title":"Iran J Parasitol"},{"key":"e_1_3_6_396_1","first-page":"12(66):1\u20137","article-title":"Single-dose liposomal amphotericin B (AmBisome\u00ae) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial","author":"Edwards T","year":"2011","unstructured":"Edwards T, Omollo R, Khalil EAG, et al. Single-dose liposomal amphotericin B (AmBisome\u00ae) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011;12(66):1\u20137.","journal-title":"Trials"},{"key":"e_1_3_6_397_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822003000200002"},{"key":"e_1_3_6_398_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762001000700021"},{"key":"e_1_3_6_399_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(87)90020-4"},{"key":"e_1_3_6_400_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2018.09.006"},{"key":"e_1_3_6_401_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S90208"},{"key":"e_1_3_6_402_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762010000200022"},{"key":"e_1_3_6_403_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-00054-7_15"},{"key":"e_1_3_6_404_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-018-6084-3"},{"key":"e_1_3_6_405_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2016.1160883"},{"key":"e_1_3_6_406_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.909282"},{"key":"e_1_3_6_407_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0337-2017"},{"key":"e_1_3_6_408_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00918"},{"key":"e_1_3_6_409_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801029-7.00014-9"},{"key":"e_1_3_6_410_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02761999000700045"},{"key":"e_1_3_6_411_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182016001980"},{"key":"e_1_3_6_412_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46652014000100001"},{"issue":"1","key":"e_1_3_6_413_1","first-page":"27","article-title":"Visceral leishmaniasis: experimental models for drug discovery","volume":"133","author":"Gupta S","year":"2011","unstructured":"Gupta S Nishi. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res. 2011;133(1):27\u201339.","journal-title":"Indian J Med Res"},{"key":"e_1_3_6_414_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003889"},{"key":"e_1_3_6_415_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(01)02147-X"},{"key":"e_1_3_6_416_1","volume-title":"Composi\u00e7\u00e3o farmac\u00eautica contendo lipossomas convencionais e lipossomas de circula\u00e7\u00e3o prolongada para o tratamento da leishmaniose visceral","year":"2012","unstructured":"Fr\u00e9d\u00e9ric Jean Georges Fr\u00e9zard, Erly Guilherme Azevedo, Raul Rio Ribeiro, Cynthia Peres Demicheli, Sydnei Magno da Silva, Simone Aparecida Rezende, inventors. Composi\u00e7\u00e3o farmac\u00eautica contendo lipossomas convencionais e lipossomas de circula\u00e7\u00e3o prolongada para o tratamento da leishmaniose visceral. BR: BR1020120052652; 2012."},{"key":"e_1_3_6_417_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024059"},{"key":"e_1_3_6_418_1","unstructured":"Russell WMS Burch RL. The principles of humane experimental technique [internet]. London (UK): Methuen; 1959. [cited 2021 Apr 6]. Available from: https:\/\/caat.jhsph.edu\/principles\/the-principles-of-humane-experimental-technique"},{"key":"e_1_3_6_419_1","unstructured":"O\u2019Keeffe A. Development of novel predictive 2D and 3D in vitro models for anti-leishmanial drug testing [internet]. 2018. [cited 2021 Apr 6].\u00a0Available from: http:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/4646919\/"},{"key":"e_1_3_6_420_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8060831"},{"key":"e_1_3_6_421_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-984-0_1"},{"key":"e_1_3_6_422_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803077-6.00009-6"},{"key":"e_1_3_6_423_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111560"},{"key":"e_1_3_6_424_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762008000400001"},{"key":"e_1_3_6_425_1","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232018236.06482018"},{"key":"e_1_3_6_426_1","volume-title":"Enap Escola (Nacional de Administra\u00e7\u00e3o P\u00fablica), editor","author":"Zago MF","year":"2018","unstructured":"Zago MF. Poder de compra estatal como instrumento de pol\u00edticas p\u00fablicas? In: Enap Escola (Nacional de Administra\u00e7\u00e3o P\u00fablica), editor. Brasilia, DF, Brazil; Enap (Nacional de Administra\u00e7\u00e3o P\u00fablica); 2018:1\u2013466."},{"key":"e_1_3_6_427_1","volume-title":"O poder de compras governamental como instrumento de desenvolvimento tecnol\u00f3gico: an\u00e1lise do caso brasileiro","author":"Squeff FDHS","year":"2014","unstructured":"Squeff FDHS. O poder de compras governamental como instrumento de desenvolvimento tecnol\u00f3gico: an\u00e1lise do caso brasileiro. Bras\u00edlia (DF): Texto para; 2014."},{"key":"e_1_3_6_428_1","doi-asserted-by":"publisher","DOI":"10.1590\/0102-311x00059219"},{"key":"e_1_3_6_429_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20966"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1970746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:23:33Z","timestamp":1770369813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1970746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":427,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/13543776.2021.1970746"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1970746","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}